BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR446597 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR446597\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07215234-5224@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:SAR446597: Phase 1/2 readout est. (NCT07215234)
DESCRIPTION:SAR446597\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR
 446597 in Participants With Geographic Atrophy Secondary to Age-related Ma
 cular Degeneration\nEstimated primary completion: 13 October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sar446597#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07215234
URL:https://assetmemo.bio/drug/sar446597#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
